Nebivolol Gp (Nebivolol)

Nebivolol is a selective β1‑adrenergic antagonist used in cardiovascular disease management.

• Hypertension: reduces systolic and diastolic blood pressure in adults with primary hypertension.
• Chronic heart failure: improves left‑ventricular ejection fraction and decreases symptoms in patients with reduced‑ejection‑fraction heart failure.
• Post‑myocardial infarction: assists in blood‑pressure control and reduces cardiac workload after an acute coronary event.

• Nebivolol selectively blocks β1‑adrenergic receptors in cardiac tissue, decreasing heart rate and contractility, which lowers cardiac output and blood pressure. In addition, it stimulates endothelial nitric oxide release, causing vasodilation and further contributing to its antihypertensive effect without significant β2 blockade.

Nebivolol may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Headache: mild to moderate pain often occurring early in therapy.
• Dizziness: sensation of light‑headedness, especially when standing quickly.
• Fatigue: generalized tiredness that may improve with continued use.
• Bradycardia: heart rate below 60 bpm in some patients.
• Nausea: occasional stomach upset or queasiness.
• Peripheral edema: mild swelling of the ankles or feet.

Serious or Rare Side Effects

• Severe bradycardia: markedly low heart rate requiring medical attention.
• Hypotension: significant drop in blood pressure causing faintness.
• Heart block: conduction disturbances that may need pacing.
• Bronchospasm: airway constriction, particularly in patients with asthma.
• Allergic reactions: rash, itching, or swelling of the face and throat.
• Liver enzyme elevation: abnormal hepatic function tests.

Before initiating Nebivolol, clinicians should evaluate patient‑specific factors and monitor for potential risks.

• Blood pressure monitoring: check regularly to ensure therapeutic control.
• Heart rate assessment: observe for excessive bradycardia, especially in patients with conduction disorders.
• Asthma or COPD caution: use carefully as β‑blockade may precipitate bronchospasm.
• Concomitant beta‑blockers: avoid duplicate therapy to prevent additive effects.
• Renal or hepatic impairment: dose adjustment may be required based on organ function.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with several medication classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid)

• Other beta‑blockers: additive cardiac depression.
• Potent CYP2D6 inhibitors (e.g., paroxetine, quinidine): increase nebivolol plasma levels.
• Non‑dihydropyridine calcium‑channel blockers (verapamil, diltiazem): may cause severe bradycardia.
• Alpha‑blockers (prazosin): risk of profound hypotension.
• Antihypertensive combinations with high‑dose diuretics: excessive blood‑pressure drop.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: monitor for additive hypotensive effect.
• Diuretics: watch for electrolyte disturbances.
• NSAIDs: may blunt antihypertensive response.
• Antidiabetic agents: monitor blood glucose as beta‑blockade can mask hypoglycemia signs.